Bacteriotherapy in Pediatric Inflammatory Bowel Disease

David Suskind13 enrolled

Overview

In this study, the investigators want to see if Bacteriotherapy (also referred to as stool transplantation) improves the symptoms and decreases inflammation in children with Inflammatory Bowel Disease (IBD). Examples of IBD are Crohn's Disease and Ulcerative Colitis. Additionally, researchers want to learn whether this experimental therapy delays the need for starting additional medications to treat pediatric IBD.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis CD

Interventions

BacteriotherapyBIOLOGICAL

Eligibility

Sex: ALLMin age: 12 YearsMax age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children ages 12-21 years old with a diagnosis of mild to moderate Ulcerative Colitis or Crohn's Disease * Willing parent to donate stool for the transplant Exclusion Criteria: * Severe Disease * History of intra-abdominal abscess, intra-abdominal fistula or stricturing * History of other systemic diseases * The patient has received TNF inhibitors to treat their IBD within two months of transplant

Locations (1)

Seattle Children's Hospital

Seattle, Washington, United States

Outcomes

Primary Outcomes

Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease Activity Index (PCDAI) Scoring

The primary outcome measure is based on estimating the responder rate. This is defined as the proportion of patients with response to therapy by a drop of 10 or more points in PUCAI/PCDAI scoring. PUCAI/PCDAI are validated activity indexes for pediatric Ulcerative colitis and Crohn's disease, respectively. PUCAI scoring ranges from 0 to 85, with disease remission less than 10, mild disease activity between 10 - 35, moderate disease activity from 35 - 65, and severe disease activity above 65. PCDAI scoring ranges from 0 to 100; with remission being less than 10, mild disease from 10 to 30, and moderate to severe disease greater than 30.

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.